scPharmaceuticals (SCPH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants John Tucker - President & CEOSteve Parsons - Senior Vice President of CommercialRachael Nokes - Chief Financial OfficerDouglas Tsao - Managing Director Conference Call Participants William Thorp - AnalystRoanna Ruiz - Senior Research AnalystStacy Ku - AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator a reminder, today's conference call is being recorded. I would now like to turn the c ...

Financial Data and Key Metrics Changes - In Q3, total revenue was $14.1 billion, up 11% year over year, with non-GAAP net income at $3.8 billion and non-GAAP earnings per share at $0.96 [25][28] - Total product revenue increased to $10.4 billion, up 15%, while services revenue rose to $3.8 billion, up 3% [25][28] - Total annual recurring revenue (ARR) ended at $30.6 billion, a 5% increase, with subscription revenue up 15% to $7.9 billion, representing 56% of total revenue [26][28] Business Line Data and Key Metrics Changes - Networking revenue grew 8%, driven by double-digit growth in switching and enterprise routing, partially offset by a decline in servers [26][28] - Security revenue surged 54%, primarily due to growth in offerings from Splunk and SASE [26][28] - Collaboration revenue increased by 4%, while observability revenue rose by 24% [26][28] Market Data and Key Metrics Changes - Product orders grew 20% year over year, with a 9% increase when excluding Splunk [27] - In geographic segments, The Americas saw a 27% increase, EMEA was up 4%, and APJC grew by 21% [27] - In customer markets, Service Provider and Cloud orders increased by 32%, Enterprise orders were up 22%, and Public Sector orders rose by 8% [27] Company Strategy and Development Direction - Cisco is focusing on AI infrastructure, with over $600 million in AI infrastructure orders from web scale customers in Q3, surpassing the original target for the fiscal year [6][11] - The company is expanding partnerships, including a significant collaboration with NVIDIA to enhance AI capabilities [12][14] - Cisco is investing in the Kingdom of Saudi Arabia as a strategic technology partner for AI infrastructure, aligning with the country's Vision 2030 [13][14] Management's Comments on Operating Environment and Future Outlook - Management noted that customer purchasing behavior remains strong despite macroeconomic uncertainties, particularly in AI transitions [36][40] - The company expects continued growth in AI orders and infrastructure, with a focus on executing and increasing capacity [86] - Management anticipates that the sovereign AI cloud opportunity will ramp up in the near term, positioning Cisco as a core system provider [14][15] Other Important Information - Cisco returned $3.1 billion to shareholders in Q3 through dividends and share repurchases, with a total of $9.6 billion returned year to date [7][29] - The company announced the retirement of CFO Scott Herren at the end of fiscal year 2025, with Mark Patterson set to take over [19][20] Q&A Session Summary Question: What are you seeing in terms of customer buying behavior given the uncertainty with tariffs? - Management indicated no significant change in purchasing behavior, with customers committed to technology transitions, particularly in AI [36][37] Question: Is 2025 expected to be a peak year for cloud CapEx? - Management believes that global cloud CapEx will continue to grow, driven by sovereign cloud strategies and enterprise AI opportunities [48][50] Question: Can you elaborate on the $600 million in AI orders? - Management clarified that the $600 million in AI orders does not include any from the new Saudi AI company, which is just starting [55][57] Question: What is the impact of tariffs on guidance for Q4? - Management has built in expectations for tariffs in the Q4 guidance, reflecting the full cost without mitigation [88][97] Question: How is Cisco participating in the Middle East AI opportunities? - Management expects significant spending in the Middle East, with discussions focused on networking, compute, security, and observability [64][66]

GCT Semiconductor Holding (GCTS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants John Schlaefer - Director & CEOEdmond Cheng - CFOCraig Ellis - Director of Research Operator Good afternoon. Thank you for attending GCT Semiconductor Holdings Inc. First Quarter twenty twenty five Financial Results Call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. Joining the call today are John Schlafer, GCT's Chief Executive ...

Red Cat Holdings (RCAT) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Christian Koji Ericson - CFOJeffrey Thompson - Founder, Chairman, President & CEOAshok Kumar - Head of Equity Research Conference Call Participants Glenn Mattson - AnalystMike Latimore - MD & Equity Analyst - AI and Communications SaaS Operator Please note this event is being recorded. During this call, management will be making forward looking statements, including statements that address Redcat's expectations for f ...

TMC the metals company (TMC) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Craig Shesky - CFOGerard Baron - Chairman and CEOJake Sekelsky - Managing Director and Head of Metals & Mining Research Conference Call Participants Matthew O'Keefe - AnalystDmitry Silversteyn - Senior Research Analyst Operator be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Dave Krabzewski, Chief Financial Officer. Please go ahead, sir. Craig S ...

Xos (XOS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants David Zlotchew - General CounselDakota Semler - CEO & ChairmanGiordano Sordoni - Co-Founder, COO & DirectorLiana Pogosyan - Acting CFO & VP of Finance Conference Call Participants Craig Irwin - Managing Director, Senior Research Analyst Operator Good day and welcome to the Exos Inc. First Quarter of twenty twenty five Earnings Call. All participants will be in a listen only mode for the duration of the call. And should you need an ...

Nortech Systems (NSYS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Andrew LaFrence - CFO & SVP of FinanceJay Miller - President & CEO Operator Good afternoon, ladies and gentlemen, and welcome to the Nortech Systems Incorporated First Quarter twenty twenty five Earnings Conference Call. With me on the line today are Jay Miller, President and Chief Executive Officer and Andrew LaFrenz, Chief Financial Officer and Senior Vice President of Finance. All lines have been placed on a listen ...

Talphera (TLPH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Raffi Asadorian - CFOVincent Angotti - CEOShakil Aslam - Chief Medical Officer Conference Call Participants None - Analyst Operator Welcome to the TULFERA First Quarter twenty twenty five Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of TULFERA's website at www.tolpera.com. You may listen to a replay of this webcast by going to the Investors section of TULFERA ...

Reliance Global Group Inc (RELI) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Theodore Ayvas - Vice PresidentEzra Beyman - CEO & Executive ChairmanJoel Markovits - Chief Financial Officer Conference Call Participants None - Analyst Operator Good day, everyone. Welcome to the Reliance Global Group First Quarter Business Update Conference Call. At this time, all participants have been placed on a listen only mode, and the floor will be open for your questions and comments after the pres ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $8,700,000, a 3% decrease compared to $9,000,000 in Q1 2024, but flat on a constant currency basis [31][32] - Gross margin for the quarter was 71%, consistent with the full year 2024, but lower than 76% in Q1 2024 due to a 23% reduction in units produced [32] - Operating loss improved by 17% to $3,900,000 compared to $4,700,000 in 2024, driven by a 12% reduction in operating expenses [32][33] - Net loss for the quarter was $1,500,000 or $0.02 per share, compared to $6,100,000 or $0.11 per share in the prior year [33] Business Line Data and Key Metrics Changes - Core product sales for CytoSorb in Q1 2025 were $8,700,000, representing a 3% year-over-year decline, but constant currency sales were approximately the same as the previous year [9][10] - International distribution and other direct sales markets showed strong performance, offsetting temporary disruptions in the German direct sales segment [10] Market Data and Key Metrics Changes - Germany accounts for approximately 40% of the company's sales, and efforts are underway to return to growth in this critical market after two years of flat performance [16] - The company is focusing on expanding its presence in Dubai to access high-growth markets in the Middle East and Africa [17] Company Strategy and Development Direction - The company aims to achieve near breakeven by the end of 2025 while preparing for the anticipated launch of DrugSorb ATR in the U.S. and Canada [35][39] - Key growth catalysts include publicizing new clinical data, simplifying customer messaging, and returning German sales to growth [14][16] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their submission for DrugSorb ATR and the potential for a positive outcome from the FDA appeal process [46][47] - The company is actively preparing for the potential commercial launch of DrugSorb ATR, emphasizing the importance of real-world data and clinical evidence [27][39] Other Important Information - The company raised $6,800,000 through a shareholder rights offering, which increased available liquidity and allowed for the release of $5,000,000 of restricted cash [33][34] - The company welcomed a new Vice President of Marketing for North America to lead the strategy for DrugSorb ATR [29][30] Q&A Session Summary Question: Can you talk about your level of confidence in getting clearance for DrugSorb ATR? - Management expressed strong confidence in the strength of their submission and the compelling data from the STAR T trial, believing the chances during the appeal process are good [46][47] Question: What happens if the appeal is denied? - Management indicated that if the appeal is unsuccessful, they could continue with a new de novo submission using a large portion of the original submission, which would result in a shorter review time [47][48] Question: Will the clinical data help with marketing or reimbursement in Europe? - Management confirmed that strong clinical data is crucial for supporting reimbursement and health technology assessment decisions in the EU [51] Question: Are there any updates on other products in development besides CytoSorb and DrugSorb ATR? - Management stated that the primary focus is currently on DrugSorb ATR, with other technologies like HemoDefend VGA being discussed for the future [60] Question: What is the visibility into the conditions in Germany for growth? - Management acknowledged the unique challenges in Germany but expressed optimism about the changes being implemented to drive operational efficiency and expected benefits in the second half of the year [66]